Association between Multiplate-measured aspirin resistance and vitamin D deficiency in stable coronary artery disease.
aspirin
aspirin resistance
stable coronary artery
vitamin D deficiency
Journal
Archives of medical sciences. Atherosclerotic diseases
ISSN: 2451-0629
Titre abrégé: Arch Med Sci Atheroscler Dis
Pays: Poland
ID NLM: 101701205
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
08
2021
accepted:
10
10
2021
entrez:
26
9
2022
pubmed:
27
9
2022
medline:
27
9
2022
Statut:
epublish
Résumé
Insufficient inhibition of platelets in patients with atherosclerosis despite antiplatelet therapy leads to important clinical consequences. The present study evaluated the role of vitamin D (VD) deficiency in aspirin resistance (AR) in patients with stable coronary artery disease (CAD) treated with aspirin. This study included 70 patients with stable CAD who had been using 100 mg aspirin for at least seven days. Serum 25-hydroxyvitamin D [25-(OH)D] concentration was measured and patients with 25-(OH)D level < 20 ng/dl were defined as the VD deficient group. A Multiplate Platelet Function Analyzer (Multiplate) device was used to evaluate AR. Patients were defined as aspirin-sensitive (AS) when their AUC was ≤ 30 U, and aspirin resistant (AR) when their AUC was > 30 U. AUC was > 30 U in 15 (21%) patients and these patients were considered AR. The mean 25-(OH)D level was 18.7 ±12.2 ng/ml in all patients. Forty-five (64%) patients were VD deficient. The rate of AR was higher in the VD deficient group than the sufficient group (29% vs. 8%, In the current study, an association was found between VD deficiency and AR in patients with stable CAD. VD supplementation may reduce platelet aggregation and overcome AR.
Identifiants
pubmed: 36161218
doi: 10.5114/amsad.2021.112242
pii: 142996
pmc: PMC9487833
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e203-e208Informations de copyright
Copyright: © 2021 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Thromb Thrombolysis. 2007 Jun;23(3):213-22
pubmed: 17186390
Platelets. 2019;30(1):81-87
pubmed: 29135309
Platelets. 2019;30(1):120-125
pubmed: 29313404
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Thromb Res. 2016 Nov;147:115-121
pubmed: 27736703
Endocr Rev. 2008 Oct;29(6):726-76
pubmed: 18694980
J Am Coll Cardiol. 2017 Jul 4;70(1):89-100
pubmed: 28662812
J Am Coll Cardiol. 2003 Mar 19;41(6):961-5
pubmed: 12651041
Endocrinol Metab Clin North Am. 2017 Dec;46(4):1039-1059
pubmed: 29080634
J Invasive Cardiol. 2012 Aug;24(8):385-9
pubmed: 22865308
Am J Med. 2014 Jan;127(1):95.e1-9
pubmed: 24384107
Am J Cardiol. 2001 Aug 1;88(3):230-5
pubmed: 11472699
Am Heart J. 2010 Jun;159(6):1044-51
pubmed: 20569718
J Proteome Res. 2007 Jul;6(7):2481-7
pubmed: 17555340
Lancet. 1991 Nov 30;338(8779):1345-9
pubmed: 1682734
FASEB J. 2014 May;28(5):2108-19
pubmed: 24522202
Lancet. 2006 Feb 18;367(9510):606-17
pubmed: 16488805
Lancet. 1990 Oct 6;336(8719):827-30
pubmed: 1976875
J Am Coll Cardiol. 2003 Sep 17;42(6):1115-9
pubmed: 13678940
Am Heart J. 1991 Dec;122(6):1588-92
pubmed: 1957753
Endocrinol Metab Clin North Am. 2017 Dec;46(4):815-843
pubmed: 29080638
Stroke. 1994 Dec;25(12):2331-6
pubmed: 7974569
Heart Vessels. 2018 Nov;33(11):1275-1281
pubmed: 29725754
N Engl J Med. 1994 May 5;330(18):1287-94
pubmed: 8145785
Osteoporos Int. 2013 Aug;24(8):2167-80
pubmed: 23468072
Lancet. 1992 Dec 12;340(8833):1421-5
pubmed: 1360557
Thromb Haemost. 1997 Sep;78(3):1003-7
pubmed: 9308744
BMJ. 1994 Jan 8;308(6921):81-106
pubmed: 8298418
Int J Cardiol. 2011 May 5;148(3):387-9
pubmed: 21396725
J Pharmacol Methods. 1980 Feb;3(2):135-58
pubmed: 7392654
PLoS One. 2010 Jan 13;5(1):e8670
pubmed: 20107497
Thromb Haemost. 2006 Dec;96(6):781-8
pubmed: 17139373
Neurol Sci. 2016 Feb;37(2):181-9
pubmed: 26573589
Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):63S-68S
pubmed: 29996660
Lancet. 2006 Jun 24;367(9528):2059-60
pubmed: 16798385